Biospring

Overview

BioSpring is a specialized CDMO focused exclusively on nucleic acid therapeutics manufacturing and analytical services. Founded in 1997, the company has established itself as a global leader in oligonucleotide and mRNA production, serving pharmaceutical and biotech companies, and academic institutions worldwide.

Manufacturing Services

BioSpring offers end-to-end manufacturing solutions across all development stages:

• Research Grade: μg to multi-gram scale production for early discovery, lead screening, and lead optimization
• Preclinical: Pre-GMP quality nucleic acids for preclinical development
• Clinical (cGMP): GMP-compliant manufacturing for IND-enabling and clinical trial materials
• Commercial (cGMP): Full-scale commercial production with proven track record supporting 9 marketed oligonucleotide programs

The company manufactures a comprehensive range of nucleic acid modalities including antisense oligonucleotides (ASOs), guide RNAs (gRNA), messenger RNA (mRNA), small interfering RNA (siRNA), CpG ODNs, and other specialized oligonucleotides.

Analytical Services

Comprehensive analytical support includes bioanalytical services, characterization, method development and transfer, method validation, and release and stability testing for both drug substance and drug product.

Integrated Services

BioSpring provides project management, process development, and regulatory support including documentation for IND, IMPD, NDA, MAA, J-NDA, BLA, and DMF submissions. The company offers process validation, technology transfer, and post-market lifecycle management support.

Quality & Regulatory

GMP certified since 2007 with FDA and ANVISA inspection history. The company combines advanced analytical solutions, continuous innovation in purification technologies, and comprehensive regulatory expertise to support clients from early development through commercial launch and post-market supply.